Clinical investigation最新文献_第7页

Neurotrophic factors and Parkinson's disease 神经营养因子与帕金森病

Clinical investigation Pub Date : 2017-01-01 DOI: 10.4172/CLINICAL-INVESTIGATION.1000129

R. Bhardwaj, R. Deshmukh

{"title":"Neurotrophic factors and Parkinson's disease","authors":"R. Bhardwaj, R. Deshmukh","doi":"10.4172/CLINICAL-INVESTIGATION.1000129","DOIUrl":"https://doi.org/10.4172/CLINICAL-INVESTIGATION.1000129","url":null,"abstract":"Neurotrophins play a major role in adult neuronal survival, maintenance and regeneration. Alterations in their levels have been implicated in various neurodegenerative disorders, including Parkinson’s disease (PD). It has been reported that, the pathophysiology of PD progress is essentially depends on various striatal signaling cascade, which consists handful of neurotrophic factors namely, cerebral dopamine neurotrophic factor (CDNF), glial derived neurotrophic factor (GDNF), mesencephalic astrocyte-derived neurotrophic factor (MANF), brain derived neurotrophic factor (BDNF), nerve growth factor (NGF). Although, the exact pathophysiology of PD is remained elusive however, the loss of dopaminergic neurons and dopamine deficiency has considered as a major consequence for the movement disability as seen in PD. It has been proposed that loss of dopaminergic neurons in PD may be conducted by inadequate neurotrophic activity which leads to neuronal apoptosis. In addition, stimulation of neurotrophic factors in the striatal brain region has been reported to be beneficial in experimental models of PD. In the current review we have detailed out the neurotrophic factors and their role in pathogenesis of Parkinson’s disease.","PeriodicalId":10369,"journal":{"name":"Clinical investigation","volume":"20 1","pages":"53-62"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83698280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Mesenchymal stem cells in the reconstruction surgery of the supraspinatus muscle lesions 间充质干细胞在冈上肌病变重建手术中的应用

Clinical investigation Pub Date : 2017-01-01 DOI: 10.4172/CLINICAL-INVESTIGATION.1000118

P. Smid, M. Komzák, R. Hart, L. Paša

{"title":"Mesenchymal stem cells in the reconstruction surgery of the supraspinatus muscle lesions","authors":"P. Smid, M. Komzák, R. Hart, L. Paša","doi":"10.4172/CLINICAL-INVESTIGATION.1000118","DOIUrl":"https://doi.org/10.4172/CLINICAL-INVESTIGATION.1000118","url":null,"abstract":"Background: The objective of the study was to demonstrate the effect of concentrated bone marrow stem cells (MSCs) to the healing of sutured tendon of the supraspinatus muscle in comparison to the same procedure performed without MSCs. We have postulated the hypothesis that MSCs enhance the healing of the sutured supraspinatus tendon to its humeral footprint. Methods and findings: None of the patients had to be excluded from our prospective randomized study. 50 patients met the indication criteria for isolated supraspinatus surgery. 25 patients (Group I) received MSCs into the supraspinatus footprint. 25 patients (Group II) was treated without the use of MSCs. Patients were examined pre-operatively, 6, 12 and 24 months after the surgery and assessment included physical examination, visual analogue scale (VAS), ASES (American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form) and Constant score. Patients underwent MRI 2 years postoperatively. Findings were compared with the preoperative results. We have found no statistically significant differences between both groups pre-operatively. After a 24-month follow-up period there were significant differences observed in all clinical outcomes. When compared results between both groups two years postoperatively, p-value (p=0.05) for the VAS score was 0.0176 and for the Constant score 0.0355. The only statistically non-significant was p-value for the ASES score comparing results from both groups at two years follow-up (p=0.085). The MRI findings at 2 years showed fully healed tissue of the rotator cuff tendon in 17 patients in the Group I, but only in 9 patients in the Group II. Conclusions: We have accepted the hypothesis that MSCs enhance the healing of the sutured supraspinatus tendon to its humeral footprint.","PeriodicalId":10369,"journal":{"name":"Clinical investigation","volume":"106 1","pages":"103-110"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73544973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Abstract B89: Neoadjuvant FOLFIRINOX in patients with resectable pancreatic cancer B89:可切除胰腺癌患者的新辅助治疗FOLFIRINOX

Clinical investigation Pub Date : 2016-12-15 DOI: 10.1158/1538-7445.PANCA16-B89

S. Shahda, M. House, C. Schmidt, A. Nakeeb, A. Sehdev, Jingmei Lin, H. Cramer, Y. Tong, J. Flynn, N. Zyromski, B. O'Neil

引用次数: 0

Abstract B86: Novel assessment of SPARC expression by hierarchical clustering in pancreatic ductal adenocarcinoma shows distinct prognostic and predictive groups 摘要:通过分级聚类对胰腺导管腺癌中SPARC表达的新评估显示出不同的预后和预测组

Clinical investigation Pub Date : 2016-12-15 DOI: 10.1158/1538-7445.panca16-b86

S. Kalloger, J. Karasinska, H. Wong, D. Renouf, D. Schaeffer

引用次数: 0

Abstract B16: Loss of SIRT6 reactivates the RNA-binding protein Lin28b to drive pancreatic cancer 摘要B16: SIRT6的缺失重新激活rna结合蛋白Lin28b，驱动胰腺癌

Clinical investigation Pub Date : 2016-12-15 DOI: 10.1158/1538-7445.panca16-b16

S. Kugel, C. Sebastián, Julien Fitamant, K. Ross, Supriya K. Saha, Esha Jain, A. Gladden, Kshitij S Arora, Y. Kato, M. Rivera, Sridhar Ramaswamy, R. Sadreyev, A. Goren, V. Deshpande, N. Bardeesy, R. Mostoslavsky

引用次数: 0

A new SAS ® macro for flexible parametric survival modeling: applications to clinical trials and surveillance data 一个新的SAS®宏灵活的参数生存建模:应用于临床试验和监测数据

Clinical investigation Pub Date : 2015-12-17 DOI: 10.4155/CLI.15.54

R. Dewar, I. Khan

引用次数: 8

A review of randomization methods in clinical trials 临床试验随机化方法综述

Clinical investigation Pub Date : 2015-12-17 DOI: 10.4155/CLI.15.53

V. Berger, Olga Antsygina

引用次数: 3

Randomized clinical trials in US hospices: challenges and the current state of the art 美国临终关怀医院的随机临床试验:挑战和现状

Clinical investigation Pub Date : 2015-12-16 DOI: 10.4155/CLI.15.52

R. Kruse, L. A. Gage, K. Washington, D. Oliver